Product
EF-009
1 clinical trial
1 indication
Indication
Pancreatic CancerClinical trial
A Phase I/IIa Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety and Efficacy Profile of EF-009 in Patients With Pancreatic CancerStatus: Not yet recruiting, Estimated PCD: 2025-12-01